Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques Following SARS-CoV-2 Vaccination and Infection.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
10 05 2021
Historique:
entrez: 11 3 2021
pubmed: 12 3 2021
medline: 12 3 2021
Statut: ppublish

Résumé

Vaccines are being rapidly developed with the goal of ending the SARS-CoV-2 pandemic. However, the extent to which SARS-CoV-2 vaccination induces serum responses that cross-react with other coronaviruses remains poorly studied. Here we define serum profiles in rhesus macaques after vaccination with DNA or Ad26 based vaccines expressing SARS-CoV-2 Spike protein followed by SARS-CoV-2 challenge, or SARS-CoV-2 infection alone. Analysis of serum responses showed robust reactivity to the SARS-CoV-2 full-length Spike protein and receptor binding domain (RBD), both included in the vaccine. However, serum cross-reactivity to the closely related sarbecovirus SARS-CoV-1 Spike and RBD, was reduced. Reactivity was also measured to the distantly related common cold alpha-coronavirus, 229E and NL63, and beta-coronavirus, OC43 and HKU1, Spike proteins. Using SARS-COV-2 and SARS-CoV-1 lentivirus based pseudoviruses, we show that neutralizing antibody responses were predominantly SARS-CoV-2 specific. These data define patterns of cross-reactive binding and neutralizing serum responses induced by SARS-CoV-2 infection and vaccination in rhesus macaques. Our observations have important implications for understanding polyclonal responses to SARS-CoV-2 Spike, which will facilitate future CoV vaccine assessment and development.

Identifiants

pubmed: 33692201
pii: JVI.00117-21
doi: 10.1128/JVI.00117-21
pmc: PMC8139699
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : F32 AI152296
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI126603
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA260476
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI146779
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI124377
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI128751
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI129797
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI142759
Pays : United States
Organisme : NIH HHS
ID : R01 OD024917
Pays : United States

Informations de copyright

Copyright © 2021 Jacob-Dolan et al.

Références

Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Cell Mol Immunol. 2020 Jun;17(6):621-630
pubmed: 32415260
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Nat Med. 2020 Apr;26(4):450-452
pubmed: 32284615
Science. 2020 Nov 27;370(6520):
pubmed: 32994364
Nature. 2020 Oct;586(7827):127-132
pubmed: 32866963
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):3048-53
pubmed: 26976607
Nature. 2020 Oct;586(7830):583-588
pubmed: 32731257
Nat Med. 2020 Nov;26(11):1694-1700
pubmed: 32884153
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
Immunity. 2020 Jul 14;53(1):98-105.e5
pubmed: 32561270
Cell. 2020 Aug 20;182(4):828-842.e16
pubmed: 32645326
BMC Infect Dis. 2013 Sep 16;13:433
pubmed: 24040960
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Nat Commun. 2020 Oct 27;11(1):5413
pubmed: 33110068
J Immunol. 2019 Jan 15;202(2):392-398
pubmed: 30617121
Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W299-302
pubmed: 15980475
Int J Biol Sci. 2020 Mar 15;16(10):1686-1697
pubmed: 32226286
Nat Commun. 2021 Jan 4;12(1):113
pubmed: 33397956
Nat Microbiol. 2020 Nov;5(11):1408-1417
pubmed: 32724171
Emerg Microbes Infect. 2020 Dec;9(1):1497-1505
pubmed: 32529906
Curr Opin HIV AIDS. 2017 May;12(3):229-240
pubmed: 28422787
Nat Commun. 2017 May 23;8:15216
pubmed: 28534504
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945
Science. 2020 Aug 14;369(6505):812-817
pubmed: 32434946

Auteurs

Catherine Jacob-Dolan (C)

Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.

Jared Feldman (J)

Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.

Katherine McMahan (K)

Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

Jingyou Yu (J)

Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

Roland Zahn (R)

Janssen Vaccines and Prevention BV, Leiden, The Netherlands.

Frank Wegmann (F)

Janssen Vaccines and Prevention BV, Leiden, The Netherlands.

Hanneke Schuitemaker (H)

Janssen Vaccines and Prevention BV, Leiden, The Netherlands.

Aaron G Schmidt (AG)

Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.
Department of Microbiology, Harvard Medical School, Boston, Massachusetts, USA.

Dan H Barouch (DH)

Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA dbarouch@bidmc.harvard.edu.
Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.

Classifications MeSH